What are the precautions for taking Pramipexole Hydrochloride/Pramipexole Tablets?

In clinical studies of Pramipexole (Pramipexole) in the treatment of Parkinson's disease (PD) and other diseases , hallucinations, movement disorders, dystonia, and sudden onset of sleep have occurred. and warnings and precautions such as somnolence, impulse control disorders, mania and delirium, psychiatric patients, ophthalmic monitoring, severe cardiovascular disease, neuroleptic malignant syndrome, dopamine agonist withdrawal syndrome (DAWS), and restless legs enlargement syndrome. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Hallucinations: Hallucinations are known as side effects of treatment with dopamine agonists and levodopa. Patients should be informed that (mainly visual) hallucinations may occur.

2. Dyskinesia: In advanced Parkinson's disease, dyskinesia may occur during the initial titration of Sifrol when combined with levodopa. If this occurs, the dose of levodopa should be reduced.

3. Dystonia: After starting or increasing the dose of pramipexole, patients with Parkinson's disease occasionally report axial dystonia, including procollagen, camptocormia and pleural tone (Pisa syndrome). Although dystonia may be a symptom of Parkinson's disease, these patients' symptoms improved after pramipexole was reduced or discontinued. If dystonia occurs, dopaminergic medication regimens should be reviewed and pramipexole dose adjustment considered.

4. Sudden onset of sleep and somnolence: Pramipexole has been associated with somnolence and sudden onset of sleep, particularly in patients with Parkinson's disease. Sudden onset of sleep during daily activities has been reported, in some cases without awareness or warning signs. Patients must be informed of this and advised to exercise caution when driving or operating machinery during treatment with the drug. Patients who experience drowsiness and/or sudden sleep attacks must avoid driving or operating machinery. Additionally, dose reduction or discontinuation of treatment may be considered. Due to possible additive effects, caution should be exercised when patients taking other sedative drugs or alcohol are combined with pramipexole.

5. Impulse control disorders:Patients should be regularly monitored for the development of impulse control disorders. Patients and caregivers should be made aware that patients treated with dopamine agonists, including pramipexole, may develop behavioral symptoms of impulse control disorders, including pathological gambling, increased sexual desire, hypersexuality, compulsive consumption or purchasing, binge eating, and compulsive eating. If such symptoms occur, dose reduction/gradual discontinuation should be considered. .

6. Mania and delirium:Patients should be regularly monitored for the development of mania and delirium. Patients and caregivers should be aware that mania and delirium may occur in patients treated with pramipexole. If such symptoms occur, dose reduction/gradual discontinuation should be considered.

7. Psychiatric patients: Psychiatric patients should only receive dopamine agonist treatment if the potential benefits outweigh the risks. Coadministration of antipsychotics with pramipexole should be avoided.

8. Ophthalmic monitoring: It is recommended to conduct ophthalmic monitoring regularly or when vision is abnormal.

9. Severe cardiovascular disease: If you suffer from severe cardiovascular disease, you should pay attention. Due to the general risk of orthostatic hypotension, monitoring of blood pressure is recommended, especially in connection with dopaminergic therapy at the beginning of treatment.

10. Neuroleptic malignant syndrome: Symptoms suggestive of neuroleptic malignant syndrome have been reported when sudden cessation of dopaminergic therapy occurs.

11. Dopamine agonist withdrawal syndrome (DAWS): DAWS has been reported to be associated with dopamine agonists, including pramipexole. To discontinue treatment in patients with Parkinson's disease, pramipexole should be tapered gradually. Limited data suggest that patients with impulse control disorders and those receiving high and/or high cumulative doses of dopamine agonists may be at increased risk for DAWS. Withdrawal symptoms may include apathy, anxiety, depression, fatigue, sweating, and pain without response to levodopa. Patients should be informed of potential withdrawal symptoms before tapering and discontinuing pramipexole. Patients should be monitored closely during tapering and discontinuation. If severe and/or persistent withdrawal symptoms occur, consider temporarily reinstating pramipexole at the lowest effective dose.

12. Restless legs enlargement syndrome: pramipexole treatment of restless legs syndrome can lead to enlargement. Intensification is when symptoms occur earlier in the evening (or even in the afternoon), symptoms increase, and symptoms spread to other extremities. The risk may increase with higher doses. Prior to treatment, patients should be informed that enhancement may occur and should be advised to contact their physician if they experience symptoms of enhancement. If an increase is suspected, consideration should be given to adjusting the dose to the lowest effective dose or discontinuing pramipexole.

Reference materials:https://en.wikipedia.org/wiki/Pramipexole